Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company

AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis

Fineline Cube Mar 2, 2025

The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical...

Company

Biointron Biologics Files for Public Offering, Aims for BSE Listing

Fineline Cube Mar 2, 2025

On February 11, Biointron Biologics released its tutoring filing report for the public offering of...

Company

Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan

Fineline Cube Mar 1, 2025

On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...

Company

BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success

Fineline Cube Feb 28, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...

Company

Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction

Fineline Cube Feb 28, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024...

Company

Viatris Q4 and Full-Year Results Show Greater China Growth

Fineline Cube Feb 28, 2025

US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In...

Company Deals

SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China

Fineline Cube Feb 28, 2025

China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing...

Company Drug

Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study

Fineline Cube Feb 28, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Deals

Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development

Fineline Cube Feb 28, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences...

Company Drug

Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy

Fineline Cube Feb 28, 2025

German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...

Company Drug

Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study

Fineline Cube Feb 28, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study

Fineline Cube Feb 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...

Company

GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor

Fineline Cube Feb 28, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...

Company Medical Device

Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study

Fineline Cube Feb 28, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...

Company Drug

Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study

Fineline Cube Feb 28, 2025

China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...

Company Drug

CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT

Fineline Cube Feb 28, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...

Company Drug

Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer

Fineline Cube Feb 28, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...

Company Drug

Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval

Fineline Cube Feb 28, 2025

China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III...

Company Drug

Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL

Fineline Cube Feb 28, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...

Company Deals

EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases

Fineline Cube Feb 27, 2025

EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to...

Posts pagination

1 … 226 227 228 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.